Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Head & Neck 1Endocrine 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 47Neoplasms 21Breast Neoplasms 19Triple Negative Breast Neoplasms 16Melanoma 15Urinary Bladder Neoplasms 14Carcinoma, Transitional Cell 14Carcinoma, Hepatocellular 13Small Cell Lung Carcinoma 11Ovarian Neoplasms 11Neoplasm Metastasis 11Colorectal Neoplasms 11Uterine Cervical Neoplasms 10Squamous Cell Carcinoma of Head and Neck 8Solid Tumors 6Head and Neck Neoplasms 6Carcinoma, Renal Cell 6Lymphoma 5Esophageal Neoplasms 5Stomach Neoplasms 4Lung Neoplasms 4Kidney Neoplasms 4Sarcoma 3Pancreatic Neoplasms 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Follicular 3Endometrial Neoplasms 3Biliary Tract Neoplasms 3Urologic Neoplasms 2Solid Tumor 2

Interventions

Paclitaxel 4pembrolizumab 2pazopanib 2Trastuzumab 2Sorafenib 2Radiotherapy, Intensity-Modulated 2Radiotherapy 2Gefitinib 2Doxorubicin 2Cisplatin 2tumor necrosis factor-alpha, CNGRC fusion protein, human 1tremelimumab 1trametinib 1tipifarnib 1spartalizumab 1sargramostim 1sapanisertib 1mercaptoundecahydrododecaborate 1lenvatinib 1fosbretabulin 1efatutazone 1durvalumab 1dabrafenib 1crolibulin 1cabozantinib 1atezolizumab 1aldesleukin 1abemaciclib 1Taxes 1Tamoxifen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Thyroid Carcinoma, Anaplastic × atezolizumab × Clear all
NCT04400474 2025-06-19

CABATEN

Grupo Espanol de Tumores Neuroendocrinos

Phase 2 Completed
93 enrolled 17 charts
CNSEndocrineHead & NeckNET

Adenocarcinoma, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡